Canadas High Quality, Low Cost Licensed Producer

September 2017
1
Disclaimers
This investor presentation is being provided in connection with a private placement (the Offering) of common shares of SVT Capital Corp. (SVT). SVT has entered into an
amalgamation agreement with Delta 9 Bio-Tech Inc. (Delta 9) pursuant to which SVT has agreed to acquire Delta 9 by way of a three-cornered amalgamation (the
Transaction), which will constitute a reverse takeover of SVT, as defined in applicable securities laws, and which is intended to close concurrently with the closing of the
Offering. As such, references in this presentation to Delta 9, our or the company shall be deemed to be a reference to SVT. Additional details regarding the Transaction
will be provided in a filing statement to be filed on SVTs SEDAR profile prior to completion of the Transaction. Any information in the filing statement that differs from
information in this presentation will supersede the information in this presentation.
This presentation contains forward-looking statements regarding Delta 9 and SVT. Forward-looking statements are statements that relate to future events or future financial
performance. In some cases, you can identify forward-looking statements by the use of terminology such as "may", "should", "intend", "expect", "plan", "anticipate", "believe",
"estimate", "project", "predict", "potential", or "continue" or the negative of these terms or other comparable terminology. These statements speak only as of the date of this
presentation. This presentation also contains financial outlooks ("Outlooks") within the meaning of applicable securities laws. The Outlooks have been prepared by our
management to provide an outlook of our activities and results and may not be appropriate for other purposes. The Outlooks have been prepared based on a number of
assumptions. The actual results of operations of our company and the resulting financial results may vary from the amounts set forth herein, and such variation may be
material. Our management believes that the Outlooks have been prepared on a reasonable basis, reflecting management's best estimates and judgments. Any Outlooks in
this presentation are made as of the date of this presentation and are based upon the information available to us as of that date.
Examples of forward-looking statements in this presentation include statements pertaining to, among other things: the Transaction; the listing of SVT as a Tier 2 Industrial
issuer on the TSX Venture Exchange (the TSXV); the completion of the Offering; the expected legalization of recreational cannabis use and the anticipated legal framework
for sales of recreational cannabis; Delta 9s plans to develop independent marketing and sales strategies for the medical and recreational markets; the potential market for
cannabis consumption following legalization of recreational use cannabis; the potential legal framework for the Manitoba retail cannabis market; Delta 9s exploration of
integration into retail sales under its Delta 9 Lifestyle Brand; the potential effect of retail expansion on sales and sales costs; the competitiveness of Delta 9s per gram
production costs; Delta 9s financial projections for the future; Delta 9s intention to enter into relationships with doctors and clinic aggregator services that refer patients to
licensed cannabis producers; the future importance of relationships with retail pharmacy chains; and the proposed use of proceeds of the Offering.*

*Continued on Next Page.

2
Disclaimers Continued from Previous Page

Material assumptions supporting these forward-looking statements include, among other things: that the Transaction and the Offering will be completed; that SVT will list on
the TSXV as a Tier 2 Industrial issuer; that recreational cannabis will be legalized and legalization will allow sales through retail cannabis shops and pharmacies;
assumptions regarding the number of consumers in the recreational use cannabis market, the consumption of such users, and the retail price of recreational use cannabis;
that retail expansion will result in greater branding and marketing opportunities and increased sales prices, but also increased overhead and sales costs; that increasing the
scale of Delta 9s operations will reduce its per gram production costs to a level that will be competitive with the industrys lowest cost producers; assumptions regarding the
amount of cannabis that can be produced per grow pod, the expected selling price of such cannabis and Delta 9s timeline for construction of grow pods; that we will be
able to obtain any necessary financing on acceptable terms; and assumptions regarding our management team's ability to implement our business plan, and general
economic and financial market conditions.
Forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, including risks related to: changes in general
economic or market conditions; our ability to complete the Transaction and the Offering; our ability to effectively implement our strategies and business plans; our need for,
and ability to obtain, necessary financing on acceptable terms or at all; the timing and amount of capital expenditures, including in respect of our phased production facilities
expansion; our ability to maintain cannabis production at a level equal to our current level of production; production of agricultural products; rising energy costs; product
transportation and disruptions; reliance on key inputs; our limited operating history; our ability to retain the services of our senior management and key employees; our ability
to maintain compliance with all governmental regulations and maintain our licenses from Health Canada; the fact that we may not be able to increase sales of our retail
cannabis offerings at expected prices; competition from other cannabis producers, including home growers of cannabis; fluctuations in the wholesale and retail price of
cannabis; potential litigation; a decrease in the demand for cannabis; political uncertainty relating to the legalization of recreational cannabis and other regulation of cannabis
generally; and other factors beyond our control. These risks, as well as risks that we cannot currently anticipate, could cause our actual results, levels of activity or
performance to be materially different from any future results, levels of activity or performance expressed or implied by the forward-looking statements in this presentation.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance.
Except as required by applicable law, including applicable securities laws, we do not intend to update any of the forward-looking statements to conform these statements to
actual results.

3
The Delta 9 Transaction
The SVT/Delta 9 Partnership
On February 28, 2017, Delta 9 and SVT announced
the Transaction, pursuant to which SVT has agreed
to acquire all of the securities of Delta 9 by way of a
three-cornered amalgamation among SVT, Delta 9
and a wholly-owned subsidiary of SVT formed for the
purpose of completing the amalgamation. The
Transaction will result in the reverse takeover of SVT
by Delta 9. Upon successful completion of the
Transaction, it is anticipated that SVT will be listed as
a Tier 2 Industrial issuer on the TSX Venture
Exchange. SVT is currently in the process of raising
up to $5.2 million by the way of the Offering, which is
expected to be comprised of a brokered private
placement of common shares of SVT at a price of
$0.65 per share. The Offering is expected to close
immediately prior to the closing of the Transaction.*

*For more information on the transaction, please refer

High Quality Medical Cannabis,
to the Filing Statement, to be filed on SEDAR under
Produced at the Delta 9 Facility
SVTs profile prior to completion of the Transaction.

4
The Delta 9 Opportunity
1. Fully licensed producer under the Access to
Cannabis for Medical Purposes Regulations
(ACMPR).
2. 80,000 square foot leased hydroponic
production facility licensed by Health
Canada (4,000 square feet currently in use).
3. Commitment to best possible quality
control.
4. Up to 845,000 square feet of utilizable
expansion space on site.
5. Additional 65 acres of vacant land for
additional expansion next to production
facility is currently available for purchase.
6. Current production facility capable of
producing more than 30,000 kilograms of
cannabis per year.
7. Currently operating the companys first
clinic and future retail outlet.

5
Canadian Cannabis Market: Recreational
Recreational use cannabis anticipated A 2016 report by Deloitte stated that the
to be legalized in 2018 with sales recreational use cannabis market (including
beginning in July. Currently licensed cannabis products and supporting products
cannabis producers can only sell to and services) is estimated to be worth
medical patients through online e- between $12.7 billion and $22.6 billion per
commerce portals and direct mail. year.
Management believes that legalization
likely to allow sales through retail (Insights into the Recreational Marijuana
cannabis shops and pharmacies. Delta Market, Deloitte, 2016)
9 intends to develop independent
marketing and sales strategies for the
medical and recreational markets.
The following table shows Delta 9s high and low estimates for the number of cannabis consumers in Canada following legalization of recreational use cannabis, as
well as the retail market value of such market (based on a retail price of $9.00 per gram). The low estimate is based on a report from Statistics Canada and the high
estimate is based on a survey conducted by Probe Research Inc. and published in the Winnipeg Free Press.

Consumers Kg/ Year/ Consumer Total Kg/ Year Demand Retail $/g Pricing Retail Market Value

Low 3,400,000 0.116 394,000 $9.00 $3,549,600,000

Estimate
High 6,800,000 0.116 788,800 $9.00 $7,099,200,000
Estimate

6
 Manitoba Cannabis Market

Delta 9 has been working with Manitoba Liquor and

Current Population Lotteries Corporation for the past 18 months on market
projections for the Manitoba retail cannabis market.
Approximately MLCC values the potential retail cannabis market for
1.3M Manitoba at between $300 - $500 million per year by
2020

No formal announcements have been made regarding a

private vs. crown corp. retail framework although Delta 9
believes that a private cost recovery regulatory
framework will be the most likely scenario.

If possible Delta 9 will explore integration into retail sales

under our Delta 9 Lifestyle Brand. All financial projections
contained in this presentation assume wholesale pricing.

*This statement constitutes forward looking information and a

Retail expansion would result in greater branding and
financial outlook for the purposes of securities laws and is marketing opportunities and increased sale prices but
subject to the risk factors and disclaimers set forth on Page 2 of
this presentation. also increased overhead and sales costs.*

7
Delta 9 Bio-Tech
1. Delta 9 currently operates in a 4,000
square foot production room (with up
to 80,000 square feet of licensed area
available for expansion).
2. Delta 9 is currently selling product to
approximately 1,800 medical
marijuana patients.
3. Delta 9 is currently selling out all
product that it is producing.
4. Applied for and received approval
from Health Canada for expansion in
order to take on new customers.
5. Construction of first 15 "grow pods"
completed using innovative, low cost
adaptation of standard shipping
containers.

8
Delta 9 Advantage
1. Experience: Delta 9 was the fourth
producer licensed in Canada for
commercial medical marijuana production.
2. Quality: Delta 9s Quality Assurance
protocols meet or exceed all Good
Production Practice requirements of
Health Canada and its hydroponic growing
methods produce a high quality finished
product. Delta 9 has never had a recall of
its products.
3. Production Cost: Relatively inexpensive
electricity, labour, and warehouse leasing
costs in Manitoba provide Delta 9 with a
natural competitive advantage.

If Delta 9 can increase the scale of its
operations in accordance with its business
*This statement constitutes forward looking
plan, management believes that its per
information and a financial outlook for the
purposes of securities laws and is subject to the gram production costs will be competitive
risk factors and disclaimers set forth on Page 2 of with the industrys lowest cost producers.*
this presentation.

9
Delta 9 High Margin Production
1. Delta 9 is one of only 58 licensed cannabis
producers under the ACMPR in Canada,
and has the only sales license in Manitoba.
2. Management believes Delta 9 enjoys a
natural "Manitoba Advantage", with
inexpensive labour and power costs
compared to other provinces.
3. Power costs for Delta 9 are just $0.05 per
kilowatt hour, compared to between $0.10
to $0.20 for many other producers.1
4. At scale, Delta 9s production cost will be as
low as $1.11 per gram. This would make
Delta 9 one of the lowest cost producers in
Canada. 2

1. Source: Manitoba Hydro 5. Significant expansion potential in current

2. Management Estimate buildings on site means Delta 9 can reach
3. This statement constitutes forward looking its desired scale of production more quickly
information and a financial outlook for the
purposes of securities laws and is subject to
and at a lower cost than many of its
the risk factors and disclaimers set forth on competitors. 3
Page 2 of this presentation.

10
Delta 9 Grow Pods Under Construction
New "Grow Pods" under 1. CSA, ETL, and Health
construction at Delta 9s Canada approved design.
production facility in 2. Storage containers are
Winnipeg, Manitoba retrofitted on site by Delta 9
staff and certified contractors.
3. Cost of conversion is only
$40,000 per grow pod.
4. Each grow pod can produce
approximately 31,500 grams
of cannabis per year.*
5. Vertical stacking maximizes
output per square metre on
site.
6. Modular design mitigates risk
*This statement constitutes forward looking information and
a financial outlook for the purposes of securities laws and is
of contamination and
subject to the risk factors and disclaimers set forth on Page 2 subsequent crop loss.
of this presentation.

11
Delta 9 Expansion Potential
Expansion Land
65 acre parcel of land adjacent to Delta
9s facility that Delta 9 would consider
purchasing if needed to further expand its
operations.
Delta 9 currently has more than enough
expansion space to meet potential growth
in the market in the near future.
*See Page 13 for a discussion of
the risks relating to the price of
cannabis and other matters.
Building One
80,000 sqft, and can
stack two levels of
Building Two grow pods. Currently
leased by Delta 9.
55,000 sq ft, and can
stack three levels of
Delta 9 is well poised to meet the grow pods. Delta 9 has
an option to lease.
upcoming demand for recreational &
Buildings 1 and 2 can house 600 grow pods,
medical cannabis. producing approximately 18,900 kilograms of
cannabis annually, accommodating anticipated
Each grow pod can produce expansion through 2020
approximately 31,500 grams of
cannabis per year.
Building Three
Based on a selling price of $7.50 per
gram, this would result in gross 350,000 sq ft, and could house
approximately 1,200 grow pods
production of approximately $235,000 producing approximately 37,800
of cannabis per year per pod*. kilograms of cannabis annually.
*This statement constitutes forward
looking information and a financial
outlook for the purposes of securities laws
and is subject to the risk factors and
disclaimers set forth on Page 2 of this
presentation.
12
 Delta 9s Grow Pods Phased Expansion Plan

Total Grow Producing Grow Support Grow Total Capital Kg per Dollars per Harvest Annualized Kg per Dollars per Year Est. Year of Completion
Pods Pods Pods Investment Harvest ($7.50/ gram) Year (5 crops/ year)
1 1 0 $40,000 6.3 $47,250 31.5 $236,250 Completed

21 15 6 $840,000 94.5 $708,750 472.5 $3,543,750 Completed

68 56 12 $2,720,000 352.8 $2,646,000 1,764 $13,230,000 2017

180 160 20 $7,200,000 1,008.0 $7,560,000 5,040 $37,800,000 2018

400 368 32 $16,000,000 2,318.4 $17,388,000 11,592 $86,940,000 2019

600 558 42 $24,000,000 3,515.4 $26,365,500 17,557 $131,827,500 Mid-2020

The table above sets forth Delta 9s goals for construction of its grow pods through mid-2020 as well as the potential earnings from such grow pods. The price per
gram of cannabis to be received by Delta 9 is based on the average price per gram that it received in 2016. The price per gram that Delta 9 receives for its cannabis
may decrease for a number of reasons, particularly if it moves from selling its product to retail customers to selling its product to wholesale customers*

*The figures in the table above constitute forward looking information and a financial outlook for the purposes of securities laws and are subject to the risk factors
and disclaimers set forth on Page 2 of this presentation.

13
Delta 9 Sales & Marketing
1. Marketing of cannabis in Canada is a challenge
due to laws limiting advertising.
2. Delta 9 launching media and sponsorship
campaign to raise awareness of its brand while
complying with cannabis marketing laws.
3. Management intends to enter into relationships
with clinic aggregator services who refer
patients to licensed cannabis producers and
doctors to enhance medical sales. Delta 9 has
existing relationships with leading clinic chains
such as Marijuana for Trauma, Bodystream,
National Access Cannabis and more.
4. Launched Delta 9 Lifestyle brand in 2017.
5. Opened first brick and mortar outlet/clinic in Q2
2017, located in busy Winnipeg location.
6. Management believes that relationships with
retail pharmacy chains will be essential as they
are integrated into the existing mail order only
supply chain.

14
Delta 9 Lifestyle Brand Cannabis Clinic Offering
1. Educational support services
for patients.
2. Physician consultation and
prescription signing.
3. Accessories.
4. Cannabidiol and hemp
products.
5. Recreational cannabis
products (pending legalization).
6. Delta 9 clothing and other
branded merchandise.

Delta 9 Lifestyle Cannabis Clinic

478 River Ave. in Osborne Village,
Winnipeg

15
Pro-Forma Capitalization
Share Issuances Number of Shares

Existing Investors1 49,856,480

Issued on Conversion of Bridge Loan2 6,888,888

Private Placement3,6 8,000,000

Corporate Finance and Finders Fee 346,154

Total 65,091,522

Total (Fully Diluted)4 5 70,584,855

1. Existing investors includes issued and outstanding shares of SVT Capital Corp. and Delta 9 Bio-Tech Inc. This number also includes the 2,000,000 Class A common shares of Delta 9 to be issued in connection with
the acquisition in connection with the acquisition of the assets of Delta 9 Bio-tech Limited Partnership.
2. Issued upon conversion of the bridge loan principal of $3,000,000 (and accrued interest of $100,000 at 10% for four month term) converted at $0.45 per share.
3. Concurrent private placement financing of $5,200,000 at $0.65 per share.
4. Includes (1) warrants exercisable at $0.155 and $0.20 per share for total proceeds of $700,000 to be exercised within 90 days after closing, (2) 8% broker warrants for bridge loan and on $3,900,000 concurrent
private placement, and 4% broker warrants on remaining $1,300,000 concurrent private placement.
5. SVT has adopted a 10% rolling stock option plan. It is estimated that 6,509,153 options will be available for issuance under the stock option plan at closing of the Transaction.
6. Some issuances have not occurred, and projections constitute forward looking statements and a financial outlook for the purposes of securities laws and are subject to the risk factors and disclaimers set forth on
Page 2 of this presentation.

16
Proposed Financings, Sources & Uses
Sources CDN $ Use Of Proceeds CDN $

Bridge Loan: Convertible Debenture1 2017 Capital Expenditures (56

$3,000,000 $2,300,600
(convertible at $0.45 per share) Grow Pods)
Concurrent Private Placement2,3
$5,200,000 Buyout of Delta-9 Limited Partners $1,250,000
(priced at $0.65 per share)

Repayment of Long Term Debt $1,100,000

General Corporate, Working

Capital & Offering Expenses $3,549,400
Purposes

Total Sources $8,200,000 Total Use Of Proceeds $8,200,000

1 Closed in May 2017

2 Anticipated closing in September 2017
3. Anticipated financing constitutes a forward looking statement and a financial outlook for the purposes of securities laws and are subject to the risk factors and disclaimers set forth on
Page 2 of this presentation.

17
Team Delta 9
Bill Arbuthnot
Co-Founder, President, Chairman
Bill has over 30 years of experience running his own businesses in sectors ranging from
internet technology to production, automated systems, security, and process control
protocols.
Duhoux-Defehr earned a BA in Business Administration and a degree in Theology in the
Prior to founding Delta 9 Bill worked in network development and engineering for one of
Canada's Big Six Banks. As Delta 9's President/Chairman and Senior Person in Charge,
Bill supervises research and development, design, construction of Delta 9's Grow Pods
and grow facilities, and day-to-day operations at the Winnipeg-based production facility.
several companies, and is a core founding member of the Delta 9 team.
John Arbuthnot
Co-Founder, CEO, Director
John Arbuthnot founded Delta 9 with his father (Bill) in 2012 as a fourth year business
student at the Asper School of Business at the University of Manitoba, where he came up
with the concept of producing medical marijuana in Canada.
traded corporations across multiple industries.
Over the past four years John has played an integral role in the development of all aspects
of Delta 9s operations. John's focus as CEO is devoted to corporate strategy, financial
planning, business development, and implementation of Delta 9's modular growth
strategy.
Brent Bottomley
CFO
Brent Bottomley is a seasoned executive with more than 30 years experience working in
the financial sector. Brent began his career as a licensed stockbroker and advisor in 1983.
He became coordinator of the Manitoba Premiers secretariat and a special advisor to the
Minister of Finance, before joining the Vision Capital Fund in 1992. Brent was a vice-
president of Corporate Finance at Merrill Lynch and Wellington West Capital before
becoming a partner at Osprey Capital Partners in 2011.
in 2008/2009.
18
Joanne Duhoux-Defehr
Director
Joanne Duhoux-Defehr is President of Triple D Developments, where she managed 1.5
million square feet of commercial and industrial buildings, including the Delta 9 site. Ms.
Netherlands, and a law degree from the University of San Francisco.
Ms. Duhoux-Defehr initially worked in the area of business litigation and intellectual
property in the US as a member of the California bar. She currently sits on the board of
Anthony Jackson
Director
Anthony Jackson is a Principal of BridgeMark Financial Corp., financial advisory firm. Mr.
Jackson has had extensive experience as a director and officer of numerous publicly
He is currently involved in two mergers involving licensed producers in the Canadian
medical marijuana industry, those being Delta 9 and Hadley Mining.
Nitin Kaushal
Director
Nitin Kaushal is a managing director in the Deals practice at PricewaterhouseCoopers
Corporate Finance Group. He has more than 25 years experience in the financial
investing, life sciences, consumer healthcare, healthcare services and medical device
industries.
Mr. Kaushals has sat on the board of numerous pharmaceutical and healthcare
companies, and held senior roles in investment banking, venture capital and consulting
firms. Brendan Wood International ranked Nitin as the Top Healthcare Investment Banker
Public Company Comparables
2018E
(C$ millions) TEV/Revenue TEV/EBITDA P/BV Revenue Growth EBITDA
Company Mkt. Cap TEV CY2017E CY2018E CY2019E CY2017E CY2018E CY2019E LTM '17E - '18E '18E - '19E Margin

Canopy $1,606 $1,510 18.3x 6.2x 3.4x neg nmf 21.4x 2.4x 197% 81% 8%
Aurora $936 $851 13.8x 5.2x na 35.9x 11.0x na 5.3x 165% na 47%
Aphria $866 $691 20.5x 6.1x 2.8x 68.5x 16.8x 7.6x 3.0x 238% 119% 36%
MedReleaf $774 $697 14.5x 5.7x 3.4x 59.2x 16.9x 9.5x 5.7x 153% 67% 34%
Cronos $400 $426 nmf 8.9x 2.9x neg 35.5x 9.0x 6.0x nmf 212% 25%
Supreme $264 $220 14.8x 3.3x 1.6x neg 12.8x 4.5x 4.4x 344% 107% 26%
OrganiGram $236 $191 11.8x 3.3x na neg 11.0x na 2.7x 256% na 30%
CanniMed $213 $172 8.5x 3.8x 2.1x nmf 13.2x 5.0x 2.1x 123% 83% 29%
CannTrust $206 $193 10.0x 4.8x 2.8x nmf 7.2x 4.1x na 107% 74% 67%
Emblem $156 $138 nmf 7.5x 2.7x neg neg 7.7x 3.2x 481% 179% neg
Hydropothecary $116 $98 7.0x 3.0x 1.4x neg 12.2x 4.6x 3.8x 138% 110% 24%
ABcann $110 $82 nmf 4.1x 1.2x neg 21.2x 3.5x 4.6x nmf 244% 19%
Invictus MD $87 $48 15.0x 2.2x 0.7x neg 8.6x 2.9x 0.9x nmf 196% 25%
MariCann $78 $67 11.4x 2.1x 0.6x neg neg 1.9x 3.5x 430% 245% neg
WeedMD $45 $42 14.3x 2.8x 0.7x neg neg 2.5x 14.2x 417% 289% neg
Average (ex. high/low) 13.2x 4.5x 2.0x 59.2x 13.8x 5.5x 3.9x 246% 150% 30%
Median 14.0x 4.1x 2.1x 59.2x 12.8x 4.6x 3.7x 217% 119% 27%

Source: Company Filings, Public Disclosure, Capital IQ (consensus estimates); updated as of Sep 6, 2017 close
1. Updated for subsequent events and calendarized to Dec 31 year end

19
Subscriber Rights
General
This document may be considered an "offering memorandum" within the meaning of applicable securities laws in certain jurisdictions. Securities legislations in certain of the
provinces in Canada provide certain purchasers with, in addition to any other rights they may have at law, a right of action for damages or recession against the Company, where
an "offering memorandum" and any amendments thereto contain a misrepresentation. These remedies must be exercised by the purchaser within the time limits prescribed by
applicable securities legislation. The following is a summary of the right of action for damages or recession available to purchasers of the offered securities under applicable
securities legislation and is subject to the express provisions of applicable securities legislation in each of the provinces identified below and the regulations, rules and policy
statements thereunder. Each purchaser should refer to the provisions of applicable securities legislation for the particulars of these rights or consult with a legal adviser.
Notwithstanding the foregoing, the Company does not consider this document to be an offering memorandum and does not intend to rely on the offering memorandum
exemption under NI 45-106 in connection with the Offering.
Statutory Rights of Action for Purchasers Resident in Alberta
This document could be designated as an offering memorandum under Alberta laws. In the event that this document is an offering memorandum, you will have certain rights
provided to you by the Securities Act (Alberta) (the Alberta Act) in the event of a misrepresentation. Where an offering memorandum contains a misrepresentation, the Alberta
Act provides that a purchaser who purchases a security offered by the offering memorandum has, without regard to whether the purchaser relied on the misrepresentation, the
following rights of action:
1. for damages against: (i) the issuer; (ii) every director of the issuer at the date of the offering memorandum; (iii) every person or company who signed the offering memorandum;
and
2. for rescission against the issuer.
If a misrepresentation is contained in a record incorporated by reference in, or deemed incorporated into, an offering memorandum, the misrepresentation is deemed to be
contained in the offering memorandum. Such rights of rescission and damages are subject to certain limitations and defences available to the issuer or other parties sued as more
particularly set forth in the Alberta Act. Time Limitations If a purchaser intends to rely on the rights described above, the purchaser must do so within strict time limitations. The
purchaser must commence the action for rescission within 180 days after the date of the transaction that gave rise to the cause of action. The purchaser must commence the
action for damages within the earlier of: (i) 180 days after the date that the purchaser first had knowledge of the facts giving rise to the cause of action; or (ii) or three years after
the date of the transaction that gave rise to the cause of action. The amount recoverable under the Securities Act (Alberta) may not exceed the price at which the securities were
offered under the offering memorandum.

Continued on Next Page

20
Subscriber Rights
Statutory Rights of Action for Purchasers Resident in Saskatchewan
This document could constitute an offering memorandum under Saskatchewan laws. In the event that this document is an offering memorandum, you will have certain rights
provided to you by The Securities Act (Saskatchewan) (the Saskatchewan Act) in the event of a misrepresentation. Where an offering memorandum, together with any
amendment to it (in this part, collectively being referred to as an offering memorandum), sent or delivered to a purchaser contains a misrepresentation, a purchaser who
purchases a security covered by the offering memorandum has, without regard to whether the purchaser relied on the misrepresentation, has the following rights of action:
1. rescission against the issuer or a selling security holder on whose behalf the distribution is made; or
2.damages against: (i) the issuer or a selling security holder on whose behalf the distribution is made; (ii) every promoter and director of the issuer or the selling security holder,
as the case may be, at the time the offering memorandum or any amendment to it was sent or delivered; (iii) every person or company whose consent has been filed respecting
the offering, but only with respect to reports, opinions or statements that have been made by them; (iv) every person who or company that, in addition to the persons or companies
mentioned in (i) to (iii) above, signed the offering memorandum or the amendment to the offering memorandum; and (v) every person who or company that sells securities on
behalf of the issuer or selling security holder under the offering memorandum or amendment to the offering memorandum.
In addition, if there is a misrepresentation (as defined in the Saskatchewan Act) in any "advertising" or "sales literature" (as those terms are defined in the Saskatchewan Act)
distributed in connection with a private placement offering and the purchaser is a resident of Saskatchewan, the purchaser has a statutory right to sue:
1. the issuer or a selling security holder of whose behalf the distribution is made;
2. every promoter or director of the issuer or selling security holder, as the case may be, at the time the advertising or sales literature was disseminated; and
3. every person who or company that, at the time the advertising or sales literature was disseminated, sells securities on behalf of the issuer or selling security holder in the
offering with respect to which the advertising or sales literature was disseminated.
Furthermore, if there is a misrepresentation in any verbal statement made to a purchaser relating to the securities purchased and the verbal statement was made either before or
contemporaneously with the purchase of the securities, the purchaser has a statutory right to sue the individual who made the verbal statement. Such rights of rescission and
damages are subject to certain limitations and defences available to the issuer or other parties sued as more particularly set forth in the Saskatchewan Act. Time Limitations If a
purchaser intends to rely on the rights described above, the purchaser must do so within strict time limitations. The purchaser must commence the action for rescission within 180
days after the date of the transaction that gave rise to the cause of action. The purchaser must commence the action for damages within the earlier of: (i) one year after the
purchaser first had knowledge of the facts giving rise to the cause of action; or (ii) or six years after the date of the transaction that gave rise to the cause of action.

Continued on Next Page

21
Subscriber Rights
Statutory Rights of Action for Purchasers Resident in Manitoba
This document could constitute an offering memorandum under Manitoba laws. In the event that this document is an offering memorandum, you will have certain rights provided to
you by The Securities Act (Manitoba) (the Manitoba Act) in the event of a misrepresentation. When an offering memorandum contains a misrepresentation, a purchaser who
purchases a security offered by the offering memorandum is deemed to have relied on the representation if it was a misrepresentation at the time of purchase and the purchase
has:
1. a right of action for damages against: (i) the issuer; (ii) every director of the issuer at the date of the offering memorandum; and (iii) every person or company who signed the
offering memorandum; and
2. a right of rescission against the issuer.
If the purchaser chooses to exercise a right of rescission against the issuer, the purchaser has no right of action for damages against a person or company referred to above.
Such rights of rescission and damages are subject to certain limitations and defences available to the issuer and other parties sued as more particularly described in the Manitoba
Act. The Securities Act (Manitoba) also provides defences in addition to those summarized here. The amount recoverable cannot exceed the price at which the securities were
offered under the offering memorandum. Additionally, in an action for damages, any defendant is not liable for all or any part of the damages that the defendant proves do not
represent the depreciation in value of the security as a result of the misrepresentation. Time Limitations If a purchaser intends to rely on the rights described above, the
purchaser must do so within strict time limitations. The purchaser must commence the action for rescission within 180 days after the date of the transaction that gave rise to the
cause of action. The purchaser must commence the action for damages within the earlier of: (i) 180 days after the purchaser first had knowledge of the facts giving rise to the
cause of action; or (ii) or two years after the date of the transaction that gave rise to the cause of action.
Statutory Rights of Action for Purchasers Resident in Ontario
This document could constitute an offering memorandum under Ontario laws. In the event that this document is an offering memorandum, you will have certain rights provided to
you by the Securities Act (Ontario) (the Ontario Act) in the event of a misrepresentation. Where an offering memorandum contains a misrepresentation, a purchaser who
purchases a security offered by the offering memorandum has, whether or not the purchaser relied on the misrepresentation, the following rights:
1. right of action for damages against the issuer and a selling security holder on whose behalf the distribution is made; or
2. if the purchaser purchased the security from a person or company referred to above, the purchaser may elect to exercise a right of rescission against the person or company. If
the purchaser exercises this right of recession, the purchaser ceases to have a right of action for damages against the person or company.
Such rights of rescission and damages are subject to certain limitations and defences available to the issuer or other parties sued as more particularly set forth in the Ontario Act.
Time Limitations If a purchaser intends to rely on the rights described above, the purchaser must do so within strict time limitations. The purchaser must commence the action
for rescission within 180 days after the date of the transaction that gave rise to the cause of action. The purchaser must commence the action for damages within the earlier of: (i)
180 days after the purchaser first had knowledge of the facts giving rise to the cause of action; or (ii) or three years after the date of the transaction that gave rise to the cause of
action.
PURCHASERS MAY HAVE RIGHTS IN ADDITION TO THOSE DESCRIBED HEREIN. FOR FURTHER INFORMATION ABOUT SUCH RIGHTS, PURCHASERS SHOULD
CONSULT A LAWYER.

22
 Contact Delta 9

John Arbuthnot Brent Bottomley

Co-Founder, CEO and Director Chief Financial Officer
john.arbuthnot@delta9.ca brent.bottomley@delta9.ca
204-470-8061 204-781-3978

www.delta9.ca
23